LYMPHOMAS

FDA fast track designation has been granted to a novel agent, DT2216, for the treatment of patient with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

Chimeric antigen receptor expansion by day 10 could be an early biomarker to predict response and survival in patients with B-cell lymphoma.

The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

Lisocabtagene maraleucel has demonstrated benefit to event-free survival for patients with relapsed/refractory large B-cell lymphoma.

Tafasitamab-cxi plus lenalidomide has been added to the NCCN Guidelines as a preferred regimen for patients with diffuse large B-cell lymphoma.

The combination of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone bests the CHOP regimen in the treatment of patients with peripheral T-cell lymphoma.

The AALL1231 trial of bortezomib showed survival benefit for children with T-cell lymphoblastic lymphoma and significantly reduced need for cranial radiotherapy in patients with T-cell acute lymphoblastic leukemia.

Significantly longer event-free survival was not demonstrated with tisagenlecleucel in the second-line setting when compared to standard-of-care second-line therapy in patients with refractory or early relapsed aggressive B-cell lymphoma.

Epcoritamab had been granted orphan drug designation by the FDA for the treatment of follicular lymphoma and is being studied in a phase 1/2 clinical trial.

In an interview with Targeted Oncology, Lori Leslie discussed the CAR T-cell product, brexucabtagene autoleucel, and its influence on both MCL and indolent lymphomas.

“It's an exciting time with all the novel agent development in relapsed indolent lymphoma,” according to Brad S. Kahl, MD.

Thomas Habermann, MD, discusses R-CHOP and how it can be improved upon as a treatment method for diffuse large B-cell lymphoma.

Golidocitinib is showing promise for the treatment of relapsed or refractory peripheral T-cell lymphoma in an ongoing phase 1/2 clinical trial.

The FDA will conduct a speedy review of the supplemental biologics license application for lisocabtagene maraleucel as second-line treatment for adult patients with relapsed or refractory large B-cell lymphoma.

Following a report of low CD4-positive T cell counts in a patient’s peripheral blood, the FDA placed a clinical hold on a phase 1 study of LB1901.

After a successful interim analysis, the PRIMO study of duvelisib for the treatment of relapsed or refractory peripheral T-cell lymphoma is now fully accrued.

Umbralisib is potentially linked to an increased risk of death in patients with lymphomas, according to an alert for clinical and patients announced by the FDA.

Patrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma

Based on data from phase 3 ECHELON-1 brentuximab vedotin in combination with chemotherapy extends survival in patients with advanced classical Hodgkin lymphoma.

Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market.

During a Targeted Oncology live event, Grzegorz S. Nowakowski, MD, discussed the case of a patient treated with tafasitamab plus lenalidomide in the second line for diffuse B-cell lymphoma.

Mark Roschewski, MD, discusses how different large cell lymphoma subtypes may respond to different therapies.

E777 is a reformulation of a previous FDA approved agent for CTLC that was pulled from the market voluntarily for improvements.

Tisagenlecleucel failed to improve event-free survival in the second-line setting of relapsed or refractory aggreesve B-cell non-Hodgkin lymphoma versus standard-of-care.

In patients with relapsed/peripheral T-cell lymphoma, the combination of duvelisib plus romidepsin was shown to be highly active.

While Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma, adverse events were common in some of these populations.

Lisocabtagene maraleucel treatment in patients with relapsed or refractory B-cell lymphoma achieves long-lasting responses, study shows.

Phase 3 ZUMA-7 study results indicate that axicabtagene ciloleucel may achieve longer event-free survival compared with standard chemotherapy.

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety.

Retrospective data from tafasitamab plus lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma correlate with real-world findings.